Final Actions Guides are now posted to accompany the October 2014 CEPAC report, “Controversies in the Management of Patients with Type 2 Diabetes.” Written as three separate guides for patients, physicians, and payers, the Action Guides distill the key recommendations from the report to guide decision-making in type 2 diabetes management. Among the resources included in these guides are evidence-based recommendations for use of second- and third-line medications for type 2 diabetes, guidance for developing coverage policies that prioritize use of high-value treatment options, tools to guide patient and clinician decisions on medication choice, and resources to support implementation of coordinated care teams for patients with diabetes. Download the action guides here.Read More
The Institute for Clinical and Economic Review (ICER) is seeking nominations of clinicians as well as patient and public representatives to serve on the New England Comparative Effectiveness Public Advisory Council (CEPAC). CEPAC is a regional body that provides objective, independent guidance on the application of medical evidence to clinical practice and payer policy decisions across New England. Supported by a consortium of New England state health policy leaders, provider groups, and payers, CEPAC holds public meetings to consider evidence reviews of medical tests, treatments, and models for health care delivery, and to provide judgments regarding how the evidence can best be used across New England to improve the quality and value of health care services. New council members will be elected to serve for a three-year term, during which they will attend two full-day meetings per year. To nominate, please send a CV and letter of intent to email@example.com. Nomination by sponsoring organizations and self-nominations are both welcome.
For more information, read the full press release here.Read More
CEPAC has released a final evidence report, titled “Controversies in the Management of Patients with Type 2 Diabetes.” The report incorporates findings from a recent public meeting of CEPAC, during which council members reviewed evidence on the effectiveness and value of add-on use of certain medications to improve diabetes control, including sulfonylureas and multiple forms of insulin, as well as two relatively new classes of medications, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. The key findings of the report, along with CEPAC’s votes, suggest that high value treatment options, such as NPH insulin (intermediate-acting human insulin), may be underutilized in many patients. The report also reviews the evidence surrounding the use of insulin pumps and continuous glucose monitors in patients with type 2 diabetes.Read More